Table 6 Disaggregated base case results including cost components and incremental results
From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Conventional care failure population | |||||
|---|---|---|---|---|---|
Cost components (€) | |||||
Drug costs (€) | Administration costs | Health state costs | Indirect costs | Adverse event cost | |
Ustekinumab | 50,352 | 312 | 55,127 | 111,987 | 14,447 |
Adalimumab | 41,942 | 996 | 57,767 | 118,962 | 19,543 |
Total and incremental results | |||||
|---|---|---|---|---|---|
Cost (€) | Incremental cost | QALYs | Incremental QALYs | ICER (€) | |
Ustekinumab | 232,225 | 14.275 | |||
Adalimumab | 239,209 | 6984 | 14.043 | − 0.232 | Dominated |
TNF-alpha failure population | |||||
|---|---|---|---|---|---|
Cost components (€) | |||||
Drug costs (€) | Administration costs | Health state costs | Indirect costs | Adverse event cost | |
Vedolizumab | 31,885 | 2293 | 62,767 | 132,895 | 14,881 |
Ustekinumab | 43,501 | 336 | 61,206 | 128,843 | 14,859 |
Total and incremental results | |||||
|---|---|---|---|---|---|
Total cost (€) | Incremental cost | Total QALYs | Incremental QALYs | ICER (€) | |
Vedolizumab | 244,721 | 14.047 | |||
Ustekinumab | 248,745 | 4023 | 14.180 | 0.133 | 30,282 |